BTIG maintains Coya Therapeutics stock buy rating, $15 target
BTIG analysts upheld their Buy rating and $15.00 price target for Coya Therapeutics (NASDAQ:COYA), following recent clinical trial data. The stock, currently trading at $7.11, has shown strong ...
Embecta raises FY2025 adjusted EBITDA margin guidance to 37% amid cost-cutting and debt reduction focus
Q1 2025 Management View CEO Dev Kurdikar emphasized the company's pivot to the next phase of transformation, focusing on three priorities: strengthening the core business, expanding the product ...